Characteristics of inhibitors in mild/moderate haemophilia A.

about

Mild hemophilia A.Inhibitors in mild/moderate haemophilia A: two case reports and a literature review.Molecular testing for disorders of hemostasis.

P2860

Q34614695-2F0EDB94-4481-4289-9D9F-4F8328EAB9CB Q37244126-52A289A1-C983-4BDC-A689-799876BBD519 Q37602557-6FE7E44F-DB48-4E11-9020-15C122D71F54

P2860

Characteristics of inhibitors in mild/moderate haemophilia A.

Item

http://www.wikidata.org/entity/Q36661826

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Characteristics of inhibitors in mild/moderate haemophilia A.

@ast

Characteristics of inhibitors in mild/moderate haemophilia A.

@en

type

Item

label

Characteristics of inhibitors in mild/moderate haemophilia A.

@ast

Characteristics of inhibitors in mild/moderate haemophilia A.

@en

prefLabel

Characteristics of inhibitors in mild/moderate haemophilia A.

@ast

Characteristics of inhibitors in mild/moderate haemophilia A.

@en

P1476

Characteristics of inhibitors in mild/moderate haemophilia A.

@en

P2093

Jacquemin M

http://www.w3.org/2001/XMLSchema#string

Peerlinck K

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of haemophilia in the United Kingdom 1981-1996.

The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development.

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.

Molecular mechanisms of mild and moderate hemophilia A.

The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4

CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development.

Factor VIII inhibitors in mild and moderate-severity haemophilia A.

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.

Factor VIII inhibitors in two families with mild haemophilia A: structural analysis of the mutations.

P304

43-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2516.2006.01365.X

http://www.w3.org/2001/XMLSchema#string

P478

12 Suppl 6

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17123393

http://www.w3.org/2001/XMLSchema#string

P921

hemophilia

hemophilia A

Characteristics of inhibitors in mild/moderate haemophilia A.

about

P2860

P2860

Characteristics of inhibitors in mild/moderate haemophilia A.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921